Is Bristol-Meyers Squibb A Good Long-Term Pick?

Bristol-Meyer Squibb's (NYSE:BMY) earnings announcement is certainly impressive and it has brought the buzz back to the stock. However, does this earnings surprise make it a buy? There are still questions about the growth prospects of its key drug, Opdivo. The earnings announcement has again helped the speculation of a takeover to build, which has added some premium to the stock price, in my opinion. We might see a pullback in the next few days if there is no movement on the M&A front. The premium added to the stock price due to the prospect of a takeover will likely dissipate in the near future.

The push in the stock price was due to the sales beat by Opdivo and Eliquis. Both these drugs generated about $240 million more in sales than the expectations of the Wall Street. Opdivo has come under pressure due to the clinical trial failure last year and these sales figures show that the sales are not falling as quickly as feared. The drug is facing stiff competition from Merck's (NYSE:MRK) Keytruda. Merck's drug has an advantage over Opdivo as it was successful where Opdivo failed, and Keytruda will likely be the drug of choice for lung cancer patients. BMY's head of research, Thomas Lynch, accepts this fact but believes that the market will be fragmented and it will not be dominated by one player. As both these drugs are almost similar in nature, he believes it will be difficult to differentiate as both work on the same platform (PD-1). Whatever the result, it is clear that Opdivo will be facing competition from Keytruda and possible new entrants. Majority of future expected sales of the company are dependent on this drug and its success, so any threat or uncertainty about Opdivo will affect the valuation of the stock.

READ FULL ARTICLE HERE